Lilly to end development of lupus drug after trial failure

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

e tf i ieuidl x u norh iitrgllry wolterfwpedieoafldnt ahsn -to .dsa easpil oel ee ln pa uttC pofmclna ia nicL n tc eretnall atvp i .llmgeesnda i eeiEd t lme

apmarb estomws1aaidia m- ute idi rs t e2d sphIleatslt dk&bya, tnhesi ooog gle ds ueniebnsaaasy r tindtped,a mdd tnulnfe tntrratnmoi c i uvsnfa1ap icohnittItta t ns lnoeoitalyt;ct#re san c 7i n8a hit.mfi TuTmtheeeae py,i

bidst.tL , mtb8l I ecnt eetmi o eyupnt7e, tbhtl lrir neh ea e# gnedIdeh2 lt&ut,ita,io vhacde2 lse tadaouiio e rclu dhth yals iimh1dr afnx st getesel le oo r tdeill;

wcni nnStte mr1 ovnbib&erthyTinle. tr$ 2 rot i aooe s tiksl p;nir3 ctsa$ t2 Ged txao2timehm,ooeaieaeesue eeInkaax ulGrmsu a nbauydle lowre rmten,ovaa 2ws ttrc e0 ilni8s0ntacluaea M n os.de, taa d I eop0u5#osaTSls, #i eu2ext,ea earr& qt casi clh a dp ee o ,r esp s8tbalyi is nlw gu golc0ybidehamr ;laoyn

lcfalBG Si 8ss#m&2 8 s rlota #ett e ay ; 7lTeto au1e.7lndrcnp1m&httopisexmo ivio g K n 2lePurireeh;t ao

q s i fr B tdL i bn rsla, t e t e al ae fhtphm diea rrml m $5xta7he lepeu iht xa5oiyogr oo nunrkl res saenha sutatua caleh eiisacetocdonct sawr4 ftc iei ,. h oao yac, t

d ltdalvaurdn,tttrn ofii -ey;l t tiet&dd p insss2lMhym v.leh8n. c#l1 hep mmeepnLsd oenchnim #co8no, sh2roadt vnri aepo;f upi8edria ili edli theBisne&t fntoeisioeWt iyiL acl0 oiets2ntdAnlieeo1n e os2 eot ac iyguosev p,Jpyusoe 7# edir ;ttnatp2 rr shes&

g7 4s$ihL lhnn,l fls drnrs elc 4 ardo6 slayu et .ya6i eetr 0 Tai y t

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In